Pediatric myocardial infarction (MI) is a rare event, but requires both immediate attention and long-term therapy. Literature on management of acute MI in pediatrics is scant and outcomes are variable [1] . We report a case of a 15-year-old male with MI.
aspirin. All the medications except aspirin were discontinued after 6 months. Thrombophilia workup revealed a homozygous MTHFR mutation for C677T gene.
Nine months after the event, he had a repeat CT angiogram which showed resolution of the filling defect in his LAD and, repeat MRI which showed no wall motion abnormalities (even in the region of scar) and preserved LV systolic function. He reached his target heart rate (197 bpm) with a good blood pressure response and no ST changes/ischemia or ventricular arrhythmias in the exercise test. On his one year follow-up he is back to his baseline swim practice.
Though MTHFR genetic mutation has been reported in adults as a cause for thrombosis [2] , there are no reported cases of MI in children with homozygous mutation of MTHFR.
The management of MI in children and young adults is complex and seems to vary depending on the age of the patient, location of the thrombus and, individual diagnose [3] [4] [5] [6] [7] . For instance, cases of coronary thrombosis related to vasculitis, lipid abnormalities, cocaine-induced vasospasm, hyper-transfusion of coagulation factors, and hypercoagulability have all been managed successfully with varied treatment modalities. The limited number of case reports highlighting the success of angioplasty, thrombolysis, and anticoagulation is not sufficient to create a robust backbone of recommendations for the treatment of this disorder in this particular age group (Table 1 ). In our patient the combination of anticoagulation, ACE inhibitors, beta blockers and aspirin seems to have assisted in the resolution of the thrombus, and proper remodeling of cardiac muscle allowing for adequate function.
The role of hypercoagulability has been a controversial cause of coronary artery thrombosis [8, 9] , yet thrombophilia evaluation is indicated in young patients with thrombosis. Reports on MI secondary to genetic mutations such as homozygous endothelial nitric oxide synthase (eNOS) T-786-C mutation, heterozygote prothrombin gene mutation (G-20210-A), and protein S deficiency have been documented in children and young adults [10] . Thrombophilia can be a cause of MI in this population and, therefore, thrombotic work up needs to be considered.
The good outcome of our patient with conservative therapy doesn't prove that all pediatric patients with MI should be treated conservatively. In fact, if the thrombus was not located at junction of LAD bifurcation, we would have possibly treated the patient with percutaneous angioplasty. Evidence behind treatment of pediatric MI is extrapolation 
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In conclusion, pediatric MI is a potentially serious disease and, there are no clear guidelines for treatment. There is as much evidence for PCI as is there for conservative treatment. Treatment needs to be individualized according to the clinical scenario until we have more data.
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